House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Gastroenterology

Inflammatory Bowel Disease Preventive Care

ACG · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The 2025 ACG preventive-care update makes vaccination, cancer screening, bone health and psychological assessment part of adult IBD management. It distinguishes patients receiving immune-modifying drugs from those without immunosuppression and includes a specific conditional statement on rotavirus vaccination after in-utero biologic exposure. The vaccine policies are framed for North America.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Make prevention part of routine IBD care

  • Coordinate health maintenance between gastroenterology, primary care and other specialists. Review vaccination status at diagnosis, transfer of care and routine remission visits rather than leaving responsibility unclear. [1]
  • Give age-appropriate vaccines before immune-modifying therapy when feasible, but do not delay appropriate IBD treatment to complete vaccination. [1]
  • Avoid live vaccines in adults receiving immune-modifying therapy. Give indicated nonlive vaccines at the earliest opportunity, without waiting for a particular biologic-cycle day or holding small molecules solely for vaccination. [1]

Review respiratory-infection protection

  • Offer annual influenza vaccination to all adults with IBD. For recipients of immune-modifying therapy, use the nonlive inactivated vaccine rather than live intranasal vaccine. [1]
  • In adults aged at least 50 with no prior pneumococcal vaccination, the guideline supports PCV20 or PCV21. It conditionally suggests these vaccines at ages 19–49 when immune-modifying treatment is used and there is no prior pneumococcal vaccination. [1]
  • For previously pneumococcal-vaccinated patients aged 19–64 on immune-modifying therapy, or aged at least 65, use the current CDC history-dependent schedule to determine additional PCV20 or PCV21 vaccination. [1]
  • The North American guidance supports RSV vaccination at age 75 or older, and at ages 50–74 with chronic conditions or other risks for severe RSV. SARS-CoV-2 vaccination should follow national recommendations. [1]

Address zoster, varicella and hepatitis B

  • ACG conditionally suggests the two-dose nonlive recombinant zoster vaccine for all adults with IBD aged at least 50, and from age 19 when taking or planning immune-modifying therapy. [1]
  • Before immune-modifying therapy, assess varicella immunity from documented chickenpox or a completed two-dose vaccine course. Avoid serological testing in previously vaccinated people because false-negative results are common; vaccinate confirmed nonimmune patients beforehand when feasible. [1]
  • Check hepatitis B status and vaccinate nonimmune patients. Before anti-TNF treatment, assess surface antigen, core antibody and surface antibody; infection and immunity are separate findings that must not be collapsed into a single antibody result. [1]
  • In immunocompromised patients, check hepatitis B surface antibody 1–3 months after completing the vaccination series to confirm response. Reactivation-risk management is a separate clinical pathway. [1]
  • Apply the national age- and risk-based recommendations for Tdap, hepatitis A, HPV and meningococcal vaccines. These are not all universal vaccine indications simply because a patient has IBD. [1]

Account for household and infant exposure

  • Keep household contacts appropriately immunized. MMR, varicella and rotavirus vaccination can be given when indicated; a varicella-vaccine recipient with a rash should avoid the immunocompromised person until it resolves, and carers should wash hands after changing a rotavirus-vaccinated infant’s diaper. [1]
  • A live rotavirus vaccine may be offered to infants exposed to biologic therapy in utero; this is a conditional recommendation supported by very-low-certainty evidence, not a general permission for every live vaccine. [1]

Plan cervical and skin-cancer screening

  • For women using immune-modifying therapy, ACG suggests annual cervical screening beginning within a year of sexual activity. For those below 30, extend to every 3 years only after three consecutive annual normal results; abnormal results need the cervical-dysplasia pathway. [1]
  • For women not receiving immune-modifying therapy, use the general average-risk cervical-screening programme rather than automatically applying the immunosuppressed schedule. [1]
  • ACG conditionally suggests annual melanoma screening for both Crohn’s disease and ulcerative colitis regardless of biologic use. [1]
  • Consider annual nonmelanoma skin-cancer screening while using thiopurines, methotrexate, JAK inhibitors or S1P receptor modulators, particularly after age 50. This recommendation is conditional with very-low-certainty evidence. [1]

Screen bone health and psychological needs

  • Screen all Crohn’s disease and ulcerative colitis patients for depression and anxiety at baseline and annually. Refer positive screens for counselling or therapy. [1]
  • In adults with conventional risk factors for low bone mineral density, consider bone-density testing at diagnosis and periodically afterwards. The recommendation is risk-based rather than universal repeated scanning. [1]
  • Counsel adults with IBD who smoke to stop smoking; the guideline makes a strong recommendation despite low-certainty evidence. [1]

Limitations and use

  • Vaccine products, age thresholds and catch-up schedules reflect this North American guideline; current national schedules, prior vaccine records and Indian availability must determine local implementation.
  • This summary does not provide complete vaccine dosing intervals, hepatitis B reactivation prophylaxis, abnormal cervical-test management or a live-vaccine specialist protocol.
  • Colorectal dysplasia surveillance and treatment of active IBD are outside this preventive-care guideline.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Inflammatory Bowel Disease Preventive Care

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: preventive care in inflammatory bowel disease acg

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Make prevention part of routine IBD care
  • Review respiratory-infection protection
  • Address zoster, varicella and hepatitis B
  • Account for household and infant exposure
  • Plan cervical and skin-cancer screening
  • Screen bone health and psychological needs
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House